Efficacy and Safety of QVA149 in Patients With Chronic Obstructive Pulmonary Disease (COPD)
A Randomized, Double-blind, Placebo Controlled, Multicentre Study to Determine the Effect of QVA149 on Lung Function in Patients With Chronic Obstructive Pulmonary Disease (COPD)
Sponsor: Novartis Pharmaceuticals
A PHASE2 clinical study on Chronic Obstructive Pulmonary Disease (COPD), this trial is completed. The trial is conducted by Novartis Pharmaceuticals and has accumulated 9 data snapshots since 2007. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
9 versions recorded-
Feb 2026 — Present [monthly]
Completed PHASE2
-
Sep 2025 — Feb 2026 [monthly]
Completed PHASE2
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE2
▶ Show 4 earlier versions
-
Aug 2018 — Jan 2021 [monthly]
Completed PHASE2
-
Jun 2018 — Aug 2018 [monthly]
Completed PHASE2
-
Feb 2017 — Jun 2018 [monthly]
Completed PHASE2
-
Jan 2017 — Feb 2017 [monthly]
Completed PHASE2
First recorded
Dec 2007
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Novartis Pharmaceuticals
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Almelo, Netherlands , Antwerp, Belgium , Bad Wörishofen, Germany , Berlin, Germany , Breda, Netherlands , Charlotte, United States , Eindhoven, Netherlands , Frankfurt, Germany , Ghent, Belgium , Heerlen, Netherlands and 12 more locations